Pfizer CFO to leave in August as GSK secures approval for urinary-tract infection drug

Pfizer announced that its chief financial officer, Dave Denton, will step down in August, ending his tenure at the company.

GSK reported that it has received regulatory approval for a new treatment targeting urinary‑tract infections, marking a significant addition to its infectious‑disease portfolio.

The briefing also noted brief updates involving several other biotech firms, including Apellis, Servier, TORL BioTherapeutics, Verastem, Corcept Therapeutics, Legend Biotech, COUR Pharmaceuticals, cAMPfield Therapeutics and LabGenius Therapeutics.